Pre-filled Syringes San Francisco Conference 2020

SMi Group 14 - 15 September 2020, San Francisco, USA.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

As part of SMi's leading Injectable conference series, we will assess digital health and connected devices, biologics, biosimilars and biocompatibility for drug device combination products, platform and device selection, regulatory insights and explore the West Coast's biotech innovators. This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

Plus, a workshop on human factors and risk management:

  • Integration of Human Factors Engineering processes in risk management saves time and money in product development
  • Effective identification of use-related risk helps inform constructive design decisions
  • Mitigation of use-related risk improves treatment outcomes for end users
  • Understanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization

Benefits of attending

  • EXPLORE the latest industry case studies in platform approaches and connected devices
  • GAIN insights from leading industry and regulatory experts on the pre-filled syringes environment
  • HEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space
  • ENGAGE in the key challenges and topics of the field in two interactive half-day workshops

Chairs for 2020

  • Shannon Clark, Principal, UserWise
  • Steven Badelt, Founder and Managing Partner, Suttons Creek, Inc.

Featured 2020 speakers include

  • Kristina Lauritsen, Combination Products Regulatory Advisor, FDA/CDER
  • Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI
  • Christine Lynn Lanning, Distinguished Scientist, Device Area Leader, Safety Assessment/Merck & Co., Inc
  • Khaudeja Bano, Senior Medical Director, Abbott Laboratories
  • Jace Blackburn, Smart Device Engineer, Genentech
  • Michael Koby, Senior Principle Scientist, Pfi zer
  • James Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
  • Walter Goodwin, Device Engineer, Device Development & Clinical Packaging Engineering, Gilead Sciences
  • Katie Atkinson, Manager Human Factors Engineering, Bigfoot Biomedical

Early-bird rates

  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.prefilled-sanfrancisco.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...